Impact of intranasal sodium hyaluronate on the short-term quality of life of patients undergoing functional endoscopic sinus surgery for chronic rhinosinusitis
Version of Record online: 3 MAR 2014
© 2014 ARS-AAOA, LLC
International Forum of Allergy & Rhinology
Volume 4, Issue 6, pages 484–487, June 2014
How to Cite
How to Cite this Article: Impact of intranasal sodium hyaluronate on the short-term quality of life of patients undergoing functional endoscopic sinus surgery for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014;4:484–487., , , et al
- Issue online: 3 JUN 2014
- Version of Record online: 3 MAR 2014
- Manuscript Accepted: 28 JAN 2014
- Manuscript Revised: 21 DEC 2013
- Manuscript Received: 21 SEP 2013
- chronic rhinosinusitis;
- disease severity;
- endoscopic sinus surgery;
- quality of life;
Functional endoscopic sinus surgery (FESS) has become the treatment of choice for patients with medically resistant chronic rhinosinusitis (CRS) and nasal polyps. Despite the consolidated use of different treatments, the postoperative period is often very painful and uncomfortable, especially during the first month. Although evidence on the effectiveness of sodium hyaluronate (SH) on postoperative care following FESS is available, data on the quality of life (QoL) from the patients’ perspective are still lacking. This study aimed to evaluate for the first time the effectiveness of nasal douche with SH in reducing patients’ discomfort during the first month following FESS.
A double-blind randomized controlled study was carried out on 124 subjects undergoing FESS for CRS with nasal polyposis. They were divided into 2 groups: group I was treated with nasal douche containing 9 mg of high molecular weight SH plus saline solution and group II was treated with saline solution alone. To assess QoL in CRS patients, the Short Form-36 (SF-36) test, the Sino-Nasal Outcome Test-22 (SNOT-22), and the visual analogue scale (VAS) questionnaires were administered.
At baseline, there were no statistically significant differences between the 2 groups. However, after 30 days of long postoperative treatments, we found clinically significant improvements in QoL of subjects treated with SH, as evidenced by all QoL scales.
Our data indicate that SH significantly improves patients’ short-term QoL following FESS in terms of both general health and specific sinonasal status.